Susquehanna International Group, LLP Amylyx Pharmaceuticals, Inc. Put Options Transaction History

Susquehanna International Group, LLP

9 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	BUY	$1.65 - $3.24 $152,625 - $299,700	92,500 Added 41.06%	317,800 $1.03 Million
Q2 2024 Aug 15, 2024	SELL	$1.62 - $2.71 $417,636 - $698,638	-257,800 Reduced 53.36%	225,300 $428,000
Q1 2024 May 07, 2024	BUY	$2.71 - $19.57 $370,999 - $2.68 Million	136,900 Added 39.54%	483,100 $1.37 Million
Q4 2023 Feb 14, 2024	BUY	$12.07 - $18.46 $2.01 Million - $3.08 Million	166,700 Added 92.87%	346,200 $5.1 Million
Q3 2023 Nov 14, 2023	BUY	$18.08 - $23.45 $1.72 Million - $2.23 Million	94,900 Added 112.17%	179,500 $3.29 Million
Q2 2023 Aug 11, 2023	SELL	$20.98 - $31.42 $398,620 - $596,980	-19,000 Reduced 18.34%	84,600 $1.82 Million
Q1 2023 May 16, 2023	BUY	$27.71 - $40.93 $1.86 Million - $2.75 Million	67,100 Added 183.84%	103,600 $3.04 Million
Q4 2022 Feb 14, 2023	SELL	$29.75 - $39.26 $9.56 Million - $12.6 Million	-321,500 Reduced 89.8%	36,500 $1.35 Million
Q3 2022 Nov 14, 2022	BUY	$17.15 - $30.92 $3.62 Million - $6.52 Million	210,900 Added 143.37%	358,000 $10.1 Million

127

44.4M

235K

530K

Ticker AMLX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,533,200
Market Cap $310M
Description
Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.